Which molecular pathology findings make an oligodendroglioma too risky for upfront vorasidenib, or which other clinical characteristics do?

I still predominantly use grade/proliferation/presence of enhancement (would be more likely to use vorasidenib in a grade 2 nonenhancing tumor) as well as clinical criteria similar to those used in Pignatti et al., PMID 11956268, or large trials like RTOG 9802 (size at diagnosis, spread across midli...